Clostridium Difficile Infections| A Pipeline Analysis Report 2018| Technavio

Technavio has published a new report on the drug development pipeline for clostridium difficile infections, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the Clostridium difficile infections market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Clostridium difficile infections.

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Clostridium difficile infections: Market overview

Clostridium difficile infections is a Gram-positive and spore-forming bacterium, which causes inflammation in the colon called colitis. People with other diseases or conditions that require longer usage of antibiotics and the older people are at higher risk of developing Clostridium difficile infection.

According to a senior market research analyst at Technavio, “Around 123,997 patients have C. difficile infections every year. In February 2015, C. difficile caused huge infections among the patients in the US, mostly aged 65 years and above, in a year. The research also mentioned Caucasian people and women were at higher risk of C. difficile infections.”

Clostridium difficile infections: Segmentation analysis

This pipeline analysis report segments the Clostridium difficile infections market based on drugs under development (discovery, pre-clinical, phase I, phase II, phase III, and registration), drug development strategies (C.difficile infections, C.difficile infections in pediatric patients, mild to moderate severity primary and recurrent C. difficile infections, primary C. difficile infections, and recurrent C. difficile infections), therapies employed (monotherapy and combination therapy), RoA (oral, intramuscular, subcutaneous, rectal, and topical, parenteral, and aerosol), therapeutic modality (small molecule, biological, vaccine, antibody, peptide, monoclonal antibody, protein, and enzyme), targets (toxins of C.difficile, bacterial cell wall, and bacterial DNA), MoA (inhibitions of toxins of C.difficile, bacterial cell wall inhibition, and inhibition of synthesis of bacterial DNA), geographical segmentation (US, Canada, Germany, UK, Poland, Japan, and Hungary) and recruitment status (recruiting, active, not recruiting, not yet recruiting, and completed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Small molecule is a chemically manufactured active substance that can enter cells easily because of its low molecular weight. Small molecules bind with specific biological macromolecules inside the body. They act as effectors and alter the activity or function of the target. In the current pipeline, 12 molecules are small molecules.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

Technavio has published a new report on the drug development pipeline for Clostridium difficile infections, with a study of the pipeline molecules.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200